The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments
Open accessAbstract
The Oxford Classification of IgA Nephropathy (IgAN) identified mesangial hypercellularity (M), endocapillary proliferation (E), segmental glomerulosclerosis (S), and tubular atrophy/interstitial fibrosis (T) as independent predictors of outcome. Whether it applies to individuals excluded from the original study and how therapy influences the predictive value of pathology remain uncertain. The VALIGA study examined 1147 patients from 13 European countries that encompassed the whole spectrum of IgAN. Over a median follow-up of 4.7 years, 86% received renin-angiotensin system blockade and 42% glucocorticoid/immunosuppressive drugs. M, S, and T lesions independently predicted the loss of estimated glomerular filtration rate (eGFR) and a lower renal survival. Their value was also assessed in patients not represented in the Oxford cohort. In individuals with eGFR less than 30 ml/min per 1.73 m(2), the M and T lesions independently predicted a poor survival. In those with proteinuria under 0.5 g/day, both M and E lesions were associated with a rise in proteinuria to 1 or 2 g/day or more. The addition of M, S, and T lesions to clinical variables significantly enhanced the ability to predict progression only in those who did not receive immunosuppression (net reclassification index 11.5%). The VALIGA study provides a validation of the Oxford classification in a large European cohort of IgAN patients across the whole spectrum of the disease. The independent predictive value of pathology MEST score is reduced by glucocorticoid/immunosuppressive therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Pencina, M. J., D' Agostino, R. B., D' Agostino, R. B., & Vasan, R. S. (2008) · Statistics in Medicine · doi:10.1002/sim.2929 · Cited by 6,493
A Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Cattran, D. C., Coppo, R., Cook, H. T., Feehally, J., Roberts, I. S. D., Troyanov, S., Alpers, C. E., Amore, A., Barratt, J., et al. (2009) · Kidney International · doi:10.1038/ki.2009.243 · Cited by 1,235
Self-citationA Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Roberts, I. S. D., Cook, H. T., Troyanov, S., Alpers, C. E., Amore, A., Barratt, J., Berthoux, F., Bonsib, S., Bruijn, J. A., et al. (2009) · Kidney International · doi:10.1038/ki.2009.168 · Cited by 1,038
Self-citationThe Commonest Glomerulonephritis in the World: IgA Nephropathy
(1987) · QJM: An International Journal of Medicine · doi:10.1093/oxfordjournals.qjmed.a068143 · Cited by 870
Wühl, E., Witte, K., Soergel, M., Mehls, O., & Schaefer, F. (2002) · Journal of Hypertension · doi:10.1097/00004872-200210000-00019 · Cited by 816
Remission of Proteinuria Improves Prognosis in IgA Nephropathy
Reich, H. N., Troyanov, S. A. A., Scholey, J. W., & Cattran, D. C. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007050526 · Cited by 639
Self-citationCorticosteroids in IgA nephropathy: a randomised controlled trial
Pozzi, C., Bolasco, P., Fogazzi, G., Andrulli, S., Altieri, P., Ponticelli, C., & Locatelli, F. (1999) · The Lancet · doi:10.1016/s0140-6736(98)03563-6 · Cited by 532
Natural history of idiopathic IgA nephropathy: Role of clinical and histological prognostic factors
D’Amico, G. (2000) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2000.8966 · Cited by 499
Corticosteroid Effectiveness in IgA Nephropathy: Long-Term Results of a Randomized, Controlled Trial
Pozzi, C., Andrulli, S., Del Vecchio, L., Melis, P., Fogazzi, G. B., Altieri, P., Ponticelli, C., & Locatelli, F. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000103869.08096.4f · Cited by 484
Cited by
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
Self-citationTrimarchi, H., Barratt, J., Cattran, D. C., Cook, H. T., Coppo, R., Haas, M., Liu, Z.-H., Roberts, I. S. D., Yuzawa, Y., Zhang, H., et al. (2017) · Kidney International · doi:10.1016/j.kint.2017.02.003 · Cited by 1,192
Self-citationRodrigues, J. C., Haas, M., & Reich, H. N. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07420716 · Cited by 555
Lai, K. N., Tang, S. C. W., Schena, F. P., Novak, J., Tomino, Y., Fogo, A. B., & Glassock, R. J. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.1 · Cited by 508
Evaluating a New International Risk-Prediction Tool in IgA Nephropathy
Barbour, S. J., Coppo, R., Zhang, H., Liu, Z.-H., Suzuki, Y., Matsuzaki, K., Katafuchi, R., Er, L., Espino-Hernandez, G., Kim, S. J., et al. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.0600 · Cited by 478
Self-citationLong-Term Outcomes in IgA Nephropathy
Pitcher, D., Braddon, F., Hendry, B., Mercer, A., Osmaston, K., Saleem, M. A., Steenkamp, R., Wong, K., Turner, A. N., Wang, K., et al. (2023) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000135 · Cited by 458
Self-citationRedefining lupus nephritis: clinical implications of pathophysiologic subtypes
Yu, F., Haas, M., Glassock, R., & Zhao, M.-H. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.85 · Cited by 340
Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy
Thompson, A., Carroll, K., A. Inker, L., Floege, J., Perkovic, V., Boyer-Suavet, S., W. Major, R., I. Schimpf, J., Barratt, J., Cattran, D. C., et al. (2019) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.08600718 · Cited by 317
Self-citationA Multicenter Study of the Predictive Value of Crescents in IgA Nephropathy
Haas, M., Verhave, J. C., Liu, Z.-H., Alpers, C. E., Barratt, J., Becker, J. U., Cattran, D., Cook, H. T., Coppo, R., Feehally, J., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016040433 · Cited by 307
Self-citationFloege, J., & Amann, K. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00272-5 · Cited by 306
New developments in the genetics, pathogenesis, and therapy of IgA nephropathy
Magistroni, R., D’Agati, V. D., Appel, G. B., & Kiryluk, K. (2015) · Kidney International · doi:10.1038/ki.2015.252 · Cited by 302
The MEST score provides earlier risk prediction in lgA nephropathy
Barbour, S. J., Espino-Hernandez, G., Reich, H. N., Coppo, R., Roberts, I. S. D., Feehally, J., Herzenberg, A. M., Cattran, D. C., Bavbek, N., Cook, T., et al. (2016) · Kidney International · doi:10.1038/ki.2015.322 · Cited by 292
Self-citationFloege, J., Barbour, S. J., Cattran, D. C., Hogan, J. J., Nachman, P. H., Tang, S. C. W., Wetzels, J. F. M., Cheung, M., Wheeler, D. C., Winkelmayer, W. C., et al. (2019) · Kidney International · doi:10.1016/j.kint.2018.10.018 · Cited by 263
Self-citationRoberts, I. S. D. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2014.92 · Cited by 263
Self-citationRovin, B. H., Barratt, J., Cook, H. T., Noronha, I. L., Reich, H. N., Suzuki, Y., Tang, S. C. W., Trimarch, H., & Floege, J. (2025) · Kidney International · doi:10.1016/j.kint.2025.04.004 · Cited by 206
Self-citationNew strategies and perspectives on managing IgA nephropathy
Selvaskandan, H., Cheung, C. K., Muto, M., & Barratt, J. (2019) · Clinical and Experimental Nephrology · doi:10.1007/s10157-019-01700-1 · Cited by 83
Self-citationThe expanding role of biomarkers in the management of IgA nephropathy
Jain, K., & Rizk, D. V. (2026) · Kidney International Supplements · doi:10.1016/j.kisu.2026.01.004 · Cited by 6
Individualised treatment effects of corticosteroids in IgA nephropathy
Hölscher, D. L., Schmitz, N. E. J., Niggemeier, L., Pilva, P., Strauch, M., Tesar, V., Barratt, J., Roberts, I. S. D., Coppo, R., Barisoni, L., et al. (2026) · eBioMedicine · doi:10.1016/j.ebiom.2026.106396 · Cited by 2
Self-citationCheung, C. K., & Mariani, L. H. (2026) · Kidney International Supplements · doi:10.1016/j.kisu.2026.01.003 · Cited by 2
Kidney biopsy in the diagnosis of immunoglobulin A nephropathy
Campbell, K. N., Chang, A., & Vivarelli, M. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1882638
Metadata
- Authors
- Coppo, R., on behalf of the VALIGA study of the ERA-EDTA Immunonephrology Working Group, Troyanov, S., Bellur, S., Cattran, D., Cook, H. T., Feehally, J., Roberts, I. S. D., Morando, L., Camilla, R., Tesar, V., Lunberg, S., Gesualdo, L., Emma, F., Rollino, C., Amore, A., Praga, M., Feriozzi, S., Segoloni, G., Pani, A., Cancarini, G., Durlik, M., Moggia, E., Mazzucco, G., Giannakakis, C., Honsova, E., Sundelin, B. B., Di Palma, A. M., Ferrario, F., Gutierrez, E., Asunis, A. M., Barratt, J., Tardanico, R., & Perkowska-Ptasinska, A.
- Venue
- Kidney International
- Publisher
- Elsevier BV
- Published
- 2014-10
- Volume
- 86
- Issue
- 4
- Pages
- 828-836
- ISSN
- 0085-2538 (ISSN-L)
- OpenAlex
- W2120366573
- Cited by
- 498
- References
- 23
- FWCI
- 28.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.